IMPALA colorectal cancer study

The cancer immune therapy MGN1703 is currently being tested in the phase III clinical trial IMPALA for the treatment of metastatic colorectal cancer.

IMPALA (Immunomodulatory MGN1703 in Patients with Advanced Colorectal Carcinoma with tumor reduction during induction treatment) is an international phase III, randomized, open-label, two-arms, and multicenter clinical trial.

The study will include patients with metastatic colorectal cancer who achieved tumor reduction after receiving first-line chemotherapy with or without biological agents.

The primary endpoint is overall survival and secondary study endpoints include progression-free survival, Quality of Life (QoL), safety and tolerability.

The study will enroll around 540 patients in eight European countries (Austria, Belgium, Estonia, France, Germany, Italy, Spain, United Kingdom) from more than 100 centers.

The coordinating study investigators are Prof. David Cunningham, MD, Department of Medicine and Director of Clinical Research, Royal Marsden Hospital in London, and Prof. Dr. Dirk Arnold, head of Klinik für Tumorbiologie Freiburg at the Albert Ludwigs University in Freiburg.

The IMPALA study is supported by leading medical associations:

• Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany
• Grupo Españiol de Tratamiento de Tumores Digestivos (TTD) in Spain
• Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) in France

The trial is open for recruitment.

• Study no. MGN1703-C06
• EudraCT no. 2014-000834-50
• Clinicaltrials.gov identifier: NCT02077868